Literature DB >> 28744562

Alterations in glutamatergic signaling in the brain of dopamine supersensitivity psychosis and non-supersensitivity psychosis model rats.

Yasunori Oda1, Yuko Fujita2, Kengo Oishi3, Yusuke Nakata3, Masayuki Takase3, Tomihisa Niitsu3, Nobuhisa Kanahara4, Yukihiko Shirayama5, Kenji Hashimoto2, Masaomi Iyo3.   

Abstract

BACKGROUND: The long-term administration of antipsychotics is known to induce dopamine supersensitivity psychosis (DSP). Although the mechanism of DSP involves mainly a compensatory upregulation of dopamine D2 receptors, the precise mechanisms underlying DSP are unknown. It is known that glutamatergic signaling plays a key role in psychosis. We thus conducted this study to investigate whether glutamatergic signaling plays a role in the development of DSP.
METHODS: Haloperidol (0.75 mg/kg/day for 14 days) or vehicle was administered to rats via osmotic mini-pump. Haloperidol-treated rats were divided into groups of DSP rats and non-DSP rats based on locomotion data. Tissue levels of glutamate, glutamine, glycine, L-serine, D-serine, and GABA and the protein expressions of N-methyl-D-aspartate receptors (NMDAR), glutamic acid decarboxylase (GAD), and serine hydroxymethyltransferase (SHMT) in the rat brain regions were examined.
RESULTS: In the DSP rats, the ratio of GABA to glutamate was significantly increased. In addition, the ratio of L-serine to glycine was increased. The striatal expressions of GAD and SHMT2 in the DSP rats were significantly increased. In contrast, the striatal expression of NMDAR2B in the non-DSP rats was significantly decreased.
CONCLUSIONS: The present study suggests that glutamatergic signaling is relatively decreased to GABA in DSP rats. Our results also showed that excessive doses of haloperidol can induce striatal NMDAR hypofunction in non-DSP rats, which could prevent the formation of tardive dyskinesia but cause treatment resistance. In view of the need for therapeutic strategies for treatment-resistant schizophrenia, further research exploring our present findings is necessary.

Entities:  

Keywords:  Antipsychotic; Dopamine D2 receptor (DRD2); Glutamate; Glutamic acid decarboxylase (GAD); N-methyl-D-aspartate receptors (NMDARs); Serine hydroxymethyltransferase (SHMT); Striatum

Mesh:

Substances:

Year:  2017        PMID: 28744562     DOI: 10.1007/s00213-017-4695-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  61 in total

Review 1.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

2.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

3.  Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels.

Authors:  Juan Bustillo; Ranee Barrow; Rodrigo Paz; Jennifer Tang; Navid Seraji-Bozorgzad; Gregory J Moore; Federico Bolognani; John Lauriello; Nora Perrone-Bizzozero; Matthew P Galloway
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

4.  The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.

Authors:  J Cartmell; J A Monn; D D Schoepp
Journal:  J Pharmacol Exp Ther       Date:  1999-10       Impact factor: 4.030

5.  Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study.

Authors:  S Silvestri; M V Seeman; J C Negrete; S Houle; C M Shammi; G J Remington; S Kapur; R B Zipursky; A A Wilson; B K Christensen; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  2000-10       Impact factor: 4.530

6.  Dopamine supersensitivity psychosis as a pivotal factor in treatment-resistant schizophrenia.

Authors:  Tomotaka Suzuki; Nobuhisa Kanahara; Hiroshi Yamanaka; Masayuki Takase; Hiroshi Kimura; Hiroyuki Watanabe; Masaomi Iyo
Journal:  Psychiatry Res       Date:  2015-03-31       Impact factor: 3.222

7.  Dopaminergic terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate.

Authors:  Garret D Stuber; Thomas S Hnasko; Jonathan P Britt; Robert H Edwards; Antonello Bonci
Journal:  J Neurosci       Date:  2010-06-16       Impact factor: 6.167

8.  Time-dependent effects of haloperidol on glutamine and GABA homeostasis and astrocyte activity in the rat brain.

Authors:  Glenn T Konopaske; Nicolas R Bolo; Alo C Basu; Perry F Renshaw; Joseph T Coyle
Journal:  Psychopharmacology (Berl)       Date:  2013-05-10       Impact factor: 4.530

9.  Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Authors:  Kenji Hashimoto; Takeshi Fukushima; Eiji Shimizu; Naoya Komatsu; Hiroyuki Watanabe; Naoyuki Shinoda; Michiko Nakazato; Chikara Kumakiri; Shin-ichi Okada; Hisanori Hasegawa; Kazuhiro Imai; Masaomi Iyo
Journal:  Arch Gen Psychiatry       Date:  2003-06

10.  Acute versus chronic haloperidol: relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release.

Authors:  P G Osborne; W T O'Connor; O Beck; U Ungerstedt
Journal:  Brain Res       Date:  1994-01-14       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.